ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.802,06
0,00%
S&P 500
5.291,34
0,00%
US Dollar vs BRL
5,2767
-0,24%
Bitcoin
70.959,73
0,48%
Brent Oil
77,975
1,12%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. TCR2 Therapeutics Inc (TCRR)

  7. TCR2 Therapeutics Inc (TCRR) Notícias

TCRR

TCR2 Therapeutics (TCRR)

TCR2 Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TCRR
DataHoraFonteTítuloCódigoCompanhia
12/06/202308:01Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:TCRRTCR2 Therapeutics Inc
06/06/202307:03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:TCRRTCR2 Therapeutics Inc
05/06/202317:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202317:46Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202317:42Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202317:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
01/06/202310:35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:TCRRTCR2 Therapeutics Inc
30/05/202317:22Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:TCRRTCR2 Therapeutics Inc
24/05/202317:57Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202308:17Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
11/05/202307:30GlobeNewswire Inc.TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
08/05/202317:05GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
05/05/202319:50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:TCRRTCR2 Therapeutics Inc
05/05/202317:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TCRRTCR2 Therapeutics Inc
20/04/202317:51Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202308:52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202308:17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TCRRTCR2 Therapeutics Inc
23/03/202307:30GlobeNewswire Inc.TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
06/03/202308:00GlobeNewswire Inc.Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
08/02/202308:45GlobeNewswire Inc.TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202318:15GlobeNewswire Inc.TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TCRRTCR2 Therapeutics Inc
05/01/202310:45GlobeNewswire Inc.TCR² Therapeutics Announces Pipeline Priorities for 2023NASDAQ:TCRRTCR2 Therapeutics Inc
23/11/202208:45GlobeNewswire Inc.TCR² Therapeutics to Present at the Piper Sandler Healthcare ConferenceNASDAQ:TCRRTCR2 Therapeutics Inc
18/11/202218:08Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:TCRRTCR2 Therapeutics Inc
09/11/202205:25TipRanksMizuho Securities Sticks to Their Buy Rating for TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202213:36TipRanksSVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)NASDAQ:TCRRTCR2 Therapeutics Inc
08/11/202208:45GlobeNewswire Inc.TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
07/11/202210:01GlobeNewswire Inc.TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of CancerNASDAQ:TCRRTCR2 Therapeutics Inc
19/10/202217:16Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:TCRRTCR2 Therapeutics Inc
29/09/202207:25TipRanksTCR2 Therapeutics (TCRR) Gets a Buy from H.C. WainwrightNASDAQ:TCRRTCR2 Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TCRR

Seu Histórico Recente

TG
FRU
Multitude
TSX
ZEM
BMO MSCI Emerging Market...
LSE
0MTW
Ishares Msci Japan Chf H...
BIT
P201O0
NLBNPIT201O0 20991231 47...
USOTC
OPWEF
Opawica Explorations (QB)
USOTC
ESRCF
ESR Cayman (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados